cpla2α

Ecopladib (PLA 725) 是一种胞浆磷脂酶 A2α (phospholipase A2α) 抑制剂，在 GLU micelle 和大鼠全血细胞中，IC50 值分别为 0.15 μM 和 0.11 μM。

D-Erythro-dihydrosphingosine (C18-Dihydrosphingosine) 可抑制花生四烯酸的释放和cPLA2α活性。

CAY10650 是高效的胞浆磷脂酶A2α抑制剂，IC50=12 nM，能够抑制脂滴形成和 PGE2 分泌。

FAAH cPLA2α-IN-1为FAAH及cPLA2α的双重抑制剂，IC50值分别为32 nM和47 nM。

Giripladib (PLA695)(PLX-695)是一种cPLA2特异性抑制剂，可抑制辐射诱导的内皮细胞磷酸化ERK 和磷酸化Akt 的增加。

PFK158 是一种选择性的PFKFB3抑制剂，IC50值为 137 nM。它可减少癌细胞中葡萄糖的摄取，ATP 的产生，乳酸的释放，并诱导细胞凋亡和自噬。它还可以增强 Colistin 对细菌的抵抗力，具有广泛的抗肿瘤活性。

Efipladib is a phospholipase inhibitor. Efipladib decreases nociceptive responses without affecting PGE2 levels in the cerebral spinal fluid.

The group IVA phospholipase A2 (PLA2), known as calcium-dependent cytosolic PLA2 (cPLA2), selectively releases arachidonic acid (AA) from membrane phospholipids, playing a central role in initiating the synthesis of prostaglandins (PGs) and leukotrienes (LTs). Pyrrophenone inhibits cPLA2α with an IC50 of 4.2 nM in enzyme assays and potently blocks the release of AA and the production of PGE2 and LTC4 in cells (IC50 = 24, 25, and 14 nM, respectively). Its action is reversible and selective, as pyrrophenone inhibits the secretory type IB and IIA PLA2s with more than a hundred-fold less potency. Pyrrophenone has also been shown to inhibit calcium ionophore (A23187)-stimulated AA release from monocytic cells, interleukin-1-induced PGE2 synthesis in mesangial cells, and the production of PGE2, LTs, and platelet-activating factor by human neutrophils, always with maximal inhibition at concentrations below 1 μM.

ASB14780 是一种 4-苯氧衍生物，是一种胞质磷脂酶 cPLA2α 抑制剂 (IC50: 20 nM)。

GK420 (AVX420) 是一种强效的胞浆磷脂酶 A2α (cPLA2α) 抑制剂，XI(50)为 0.0016。GK420 能够抑制花生四烯酸的释放，EC50为 0.09 μM，并在癌症研究中有重要应用。

Cytosolic phospholipase A2α (cPLA2α) specifically catalyzes the hydrolysis of arachidonic acid from thesn-2-ester position of membrane phospholipids, playing a central role in initiating the synthesis of prostaglandins and leukotrienes, both important mediators of the inflammatory process.1CAY10641 is an inactive alcohol derivative of a highly potent (IC50= 12 nM) cPLA2α inhibitor.2The parent compound demonstrates strong anti-inflammatory effects when applied topically at a dose of 0.1 mg ear in a mouse model of acute irritant contact dermatitis.2CAY10641 is rapidly cleared from the blood stream (only 0.5 μg ml remains 30 minutes after 10 mg kg intravenous administration to mice).2However, no other biological effects have been reported. 1.Schaloske, R.H., and Dennis, E.A.The phospholipase A2 superfamily and its group numbering systemBiochemica et Biophysica Acta17611246-1259(2006) 2.Drews, A., Bovens, S., Roebrock, K., et al.1-(5-carboxyindol-1-yl)propan-2-one inhibitors of human cytosolic phospholipase A2α with reduced lipophilicity: Synthesis, biological activity, metabolic stability, solubility, bioavailability, and topical in vivo activityJournal of Medicinal Chemistry535165-5178(2010)

Phospholipase A2 (PLA2) catalyzes the hydrolysis of phospholipids at the sn-2 position leading to the production of lysophospholipids and free fatty acids. Calcium-dependent cytosolic PLA2 (cPLA2α) is a 85 kDa enzyme that plays a key role in the arachidonic cascade and the inflammatory response associated with this metabolic pathway. CAY10502 is a potent inhibitor of calcium-dependent cytosolic PLA2α (cPLA2α) with an IC50 value of 4.3 nM for the purified enzyme from human platelets. It inhibits arachidonic acid mobilization from A23187-stimulated or TPA-stimulated human platelets with IC50 values of 570 and 0.9 nM, respectively.

Potent and selective cytosolic phospholipase A2 alpha (cPLA2α) inhibitor (IC50 = 20 nM). Selective for cPLA2α over secreted PLA2α (sPLA2α; exhibits no inhibition at 10 μM). Inhibits cPLA2α-dependent inflammatory responses in vitro in guinea pig and human whole-blood assays. Improves diet-induced liver injury and CCl4-induced hepatic fibrosis in vivo. Orally bioavailable.